Sarcoma — Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Citation(s)
A Phase I, Open Label, Maximum Tolerated Dose-Finding Study to Evaluate the Safety and Tolerability of 90Y-DOTA-tyr3-Octreotide Administered by Intravenous Infusion to Children With Refractory Somatostatin-Receptor Positive Tumors